Identification of downstream target genes regulated by the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate signal pathway in pulmonary hypertension

Lihui Zou¹, Xiaomao Xu², Zhenguo Zhai³, Ting Yang³, Junhua Jin¹, Fei Xiao¹ and Chen Wang³,⁴

Abstract

Objective: To investigate the downstream target genes regulated by the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO-sGC-cGMP) signal pathway and their possible roles in the pathogenesis of pulmonary hypertension (PH).

Methods: Digital gene expression tag profiling was performed to identify genes that are differentially expressed after activation of the NO-sGC-cGMP signal pathway in human pulmonary artery smooth muscles cells using 8-bromo-cyclic guanosine monophosphate, BAY 41-2272 and BAY 60-2770. Results were confirmed using real-time polymerase chain reaction. Gene ontology and signal transduction network analyses were also performed.

Results: A number of genes were differentially expressed, including MMP1, SERPINB2, GREM1 and IL8. A total of 68 gene ontology terms and seven pathways were found to be associated with these genes. Most of these genes are involved in cell proliferation, cell migration and apoptosis, which may contribute to the pathological pulmonary vascular remodelling in PH.

Conclusion: These results may provide new insights into the molecular mechanisms of PH.

¹Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, China
²Department of Respiratory and Critical Care Medicine, Beijing Hospital, Ministry of Health, Beijing, China
³Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Ministry of Health, Beijing, China
⁴National Clinical Research Center of Respiratory Medicine, Beijing, China

Corresponding author:
Chen Wang, China-Japan Friendship Hospital, Ministry of Health, 2 Yinghua Dongjie, Hepingli, Beijing 100029, China.
Email: cyh-birm@263.com

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Pulmonary hypertension, NO-sGC-cGMP pathway, digital gene expression tag profiling array, differentially expressed genes, gene ontology, signalling pathway

Introduction
Pulmonary hypertension (PH) is a serious disease characterized by elevated blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries, leading to shortness of breath, dizziness, weakness and even symptoms of shock symptoms such as fainting. Without treatment, the disorder will progress rapidly to right heart failure and death within 3 years of diagnosis.

The pathogenesis of PH is not completely understood, but multiple studies have suggested that an imbalance of vasoconstriction/vasodilation and proliferation/antiproliferation may be involved. Nitric oxide (NO), which is produced by NO synthase from L-arginine, is an important vascular modulator in the development of PH. It exerts its biological activity mainly by activating soluble guanylate cyclase (sGC) to synthesize the second messenger cyclic guanosine monophosphate (cGMP), which promotes vasodilation and inhibits smooth muscle cell growth and proliferation, neuronal transmission, host defences, leukocyte recruitment, platelet aggregation and vascular remodelling through a number of downstream targets.

Impairment of the NO-sGC-cGMP pathway, associated with dysregulation of NO production, sGC activity and cGMP degradation, has been shown to contribute to the progression of PH. A number of sGC stimulators and activators that can bind to the β subunit of sGC and stimulate it in a direct or indirect way have been identified, including 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), 3-(4-amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine (BAY 41-2272), 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholino)-4,6-pyrimidinediamine (BAY 41-8543) and riociguat (BAY 63-2521). They can act as potent pulmonary vasodilators, decreasing the mean pulmonary arterial pressure and vascular resistance, and have been shown to reverse structural lung vascular remodelling and right heart hypertrophy in PH.

Riociguat is the first sGC stimulator to undergo clinical study. In clinical trials it significantly improved the pulmonary vascular haemodynamics in pulmonary arterial hypertension and chronic thromboembolic PH with no serious adverse events. In contrast, a specific inhibitor of sGC, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, has been shown to block the rise in cGMP and the antiproliferative action of the NO-sGC-cGMP pathway.

To date, studies suggest that once cGMP is produced, its effects could be executed through three main groups of cellular target molecules: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels and phosphodiesterases (PDEs). The PDE inhibitor sildenafil is used to treat idiopathic PH. However, besides these three groups of molecules, little is known about the downstream target genes of the NO-sGC-cGMP pathway and the signalling events regulating gene expression. Using genome-wide technologies that can measure the expression of thousands of genes simultaneously, differences in gene expression in response to particular treatments can be measured. In the present study, digital gene expression tag profiling was used to measure differences in gene expression in human pulmonary artery smooth muscle cells treated with two sGC agonists and a
cGMP analogue. Gene ontology analysis of the differential gene expression was then used to reveal the candidate genes involved in the activation of NO-sGC-cGMP pathway.

**Materials and methods**

*Digital gene expression tag profiling*

Human pulmonary artery smooth muscle cells isolated from patients with PH were generously provided by Dr Jun Wang from Capital Medical University, Beijing, China. They were cultured in smooth muscle cell medium (ScienCell Research Laboratories, Carlsbad, CA, USA) supplemented with 2% fetal bovine serum and 1% smooth muscle cell growth supplement (ScienCell Research Laboratories) and maintained at 37°C in a humidified atmosphere of 5% carbon dioxide. The sGC agonists BAY 41-2272 (an NO-independent but haem-dependent sGC stimulator) and BAY 60-2770 (an NO- and haem-independent sGC activator) for digital gene expression tag profiling were generously provided by Professor Johannes-Peter Stasch from Bayer Schering Pharma AG, Cardiology Research, Pharma Research Centre, Germany. These were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 5% carbon dioxide. The sGC agonists BAY 41-2272 (an NO-independent but haem-dependent sGC stimulator) and BAY 60-2770 (an NO- and haem-independent sGC activator) for digital gene expression tag profiling were generously provided by Professor Johannes-Peter Stasch from Bayer Schering Pharma AG, Cardiology Research, Pharma Research Centre, Germany. These were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 5% carbon dioxide. The sGC agonists BAY 41-2272 (an NO-independent but haem-dependent sGC stimulator) and BAY 60-2770 (an NO- and haem-independent sGC activator) for digital gene expression tag profiling were generously provided by Professor Johannes-Peter Stasch from Bayer Schering Pharma AG, Cardiology Research, Pharma Research Centre, Germany. These were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 5% carbon dioxide. The sGC agonists BAY 41-2272 (an NO-independent but haem-dependent sGC stimulator) and BAY 60-2770 (an NO- and haem-independent sGC activator) for digital gene expression tag profiling were generously provided by Professor Johannes-Peter Stasch from Bayer Schering Pharma AG, Cardiology Research, Pharma Research Centre, Germany. These were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 5% carbon dioxide.

Smooth muscle cells (1 × 10^6) were treated with 2 μl of 100 μmol/l BAY 41-2272 for 8 h, 0.2 μl of 10 μmol/l BAY 41-2272 for 24 h or 2 μl of 100 μmol/l 8-bromo-cGMP (8-Br-cGMP; Sigma-Aldrich, St Louis, MO, USA) for 8 h. Controls were treated with DMSO (2 μl or 0.2 μl as controls for BAY 41-2272 and BAY 60-2770, respectively) or 2 μl double-distilled H_2O (controls for 8-Br-cGMP) for the same time periods. The cells (2 × 10^6) were then harvested at the indicated time points.

Total RNA was extracted using TRIzol reagent according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Magnetic oligo-beads were used to isolate the mRNA from 6 μg of total RNA. First- and second-strand cDNA was synthesized using oligo(dT) primers, purified using a Qiaquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions, and digested with DNase I in order to produce a substantial enrichment of fragments about 200 bp in length. The samples (20 μl) were then loaded onto 1.2% agarose gel (Invitrogen) and fragments between 100 and 300 bp were extracted using a Qiaquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. The 5’ and 3’ ends of the fragments were end-repaired. The samples were purified and ligated to genomic adapters (Illumina, San Diego, CA, USA) and then loaded onto 2% agarose gel and separated by electrophoresis (120 V for 30 min), and the fragments between 100 and 300 bp were isolated from the gel and purified using the Qiaquick Gel Extraction Kit. A polymerase chain reaction (PCR) of the gel-purified cDNA (total volume 50 μl) was performed using DNA polymerase and primers provided by Illumina according to the manufacturer’s instructions. After 15 cycles of PCR amplification, the sample were loaded onto 1.2% agarose gels and fragments between 100 and 300 bp were purified from the gel again. The samples were then quantified spectrophotometrically using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and sequenced using a HiSeq™ 2000 system (Illumina).

**Determination of differentially expressed genes**

To compare the differential expression of genes across samples, the raw data was collected and filtered to remove low quality tags, adaptor tags and tags with a single copy number. The gene expression levels
were determined by the number of raw clean tags in each library normalized to the transcripts per million clean tags. A significant difference was defined as a $P$-value < 0.05, a false discovery rate ≤0.001 and a ratio ≥2 for the sequence counts across the libraries. Upregulated genes were defined as >2.0 × expression in controls, and downregulated genes were defined as <0.5 × expression in controls.

**Quantitative real-time PCR**

Quantitative real-time PCR was performed to validate the digital gene expression results. Human pulmonary artery smooth muscle cells for quantitative real-time PCR were purchased from ScienCell Research Laboratories and were cultured in the same smooth muscle cell medium as described above. Smooth muscle cells (1 × 10⁶) were treated with 2 μl of 100 μmol/l BAY 41-2272 (Sigma-Aldrich) for 8 h. Controls were treated with 2 μl DMSO for the same time period. The cells (2 × 10⁶) were then harvested.

Total RNA was extracted using TRIzol reagent according to the manufacturer’s instructions. First-strand cDNA was generated with random primers using a SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen). Real-time PCR was performed using the iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) with SYBR® Premix Ex TaqTM II (Takara Biotech Co., Dalian, China) according to the manufacturer’s protocol. The target genes were MMP1, SERPINB2, GREM1, IL8 and actin. The two-step PCR protocol included one cycle of 95°C for 30 s, and 40 cycles of 95°C for 5 s and 60°C for 30 s. The PCR reaction required 9.9 μl of distilled water, 12.5 μl of 2 × SYBR® Premix Ex TaqTM II, 0.8 μl of each primer, and 1 μl of DNA template in a total volume of 25 μl. Experiments were performed in triplicate and were repeated at least three times. The threshold cycle (Ct) values for relative quantification of gene expression were calculated using the $2^{-\Delta\Delta Ct}$ method and normalized to β-actin. The PCR primers for MMP1 were GGTTCTCTGAG GGTCAGGCAG (forward) and AGTTCA TGAGCTGCAACACG (reverse). The primers for SERPINB2 were ATGGTCTACATGGGCTCCAG (forward) and CGCAGA CTTCTACCAAAACA (reverse). The primers for GREM1 were GCTCTGGCATTC AGAGAAACC (forward) and AAATTGCCTAGCCTGAGAA (reverse). The primers for IL8 were TAGCATAATTGAGGCA AGG (forward) and AAACCAAGGCCAC AGTGGAAC (reverse). The primers for the actin gene were GGCGGCACACCATTG TACCT (forward) and AGGGCCCG ACTCGTCAT (reverse).

**Gene ontology analysis of the differentially expressed genes**

Gene ontology (GO) analysis is a commonly used technique to determine the main functions of differentially expressed genes according to the GO database.¹⁸ A $P$-value was determined for the GO terms and a corrected $P$-value calculated for the differentially expressed genes as follows:

$$P = 1 - \sum_{i=0}^{m-1} \frac{M \binom{N-M}{n-i} \binom{N}{n}}{N \binom{N-M}{n}}$$

where $N$ is the total number of genes with that GO term, $n$ is the number of genes with that GO term in the differentially expressed genes, $M$ is the total number of genes within the particular GO category, $m$ is the number of genes within the particular GO category in the differentially expressed genes, and $i$ is the number from 0 to $m-1$. The threshold of significance was defined as a corrected $P$-value < 0.05.
Pathway analysis of the differentially expressed genes

Pathway analysis was based on the Kyoto Encyclopedia of Genes and Genomes (KEGG), a comprehensive pathway-related database.\textsuperscript{19} P-values were calculated using the above equation, where \( N \) is the total number of genes with that pathway annotation, \( n \) is the number of genes with that pathway annotation in the differentially expressed genes, \( M \) is the total number of genes within the particular pathway category, \( m \) is the number of genes within the particular pathway category in the differentially expressed genes, and \( i \) is the number from 0 to \( m - 1 \). The threshold of significance was defined as a Q-value \( \leq 0.05 \), where the Q-value is an analogue of the \( P \)-value incorporating false discovery rate-based multiple testing correction.

Statistical analyses

All data were expressed as the mean \( \pm \) SD. Differential gene expression levels were based on log\(_2\) ratios among the different groups. Statistical comparisons were performed using the Student’s \( t \)-test for analyzing two-group data. The threshold of significance was defined as a \( P \)-value \(< 0.05\).

Results

Differentially expressed genes

Compared with controls, 539 upregulated genes and 367 downregulated genes were identified in cells treated with 8-Br-cGMP, and 993 upregulated genes and 1002 downregulated genes were identified in cells treated with BAY 41-2272 (100 \( \mu \text{mol/l} \) for 8 h) (Figure 1). In addition, 219 and 143 genes were significantly upregulated and 353 and 351 genes were significantly downregulated after treatment with BAY 41-2272 (10 \( \mu \text{mol/l} \) for 24 h) and BAY 60-2770 (10 \( \mu \text{mol/l} \) for 24 h), respectively. A total of 84 of the upregulated genes and 87 of the downregulated genes showed similar variation trends in all four groups, suggesting that activation of the NO-sGC-cGMP pathway might affect expression of a group of important downstream factors. Nine genes that were significantly up- or downregulated compared with controls when the NO-sGC-cGMP pathway was activated are shown in Table 1. Interestingly, these differentially expressed genes are involved in the

![Figure 1](image-url)  

**Figure 1.** Differentially expressed genes (DEGs) in pulmonary artery smooth muscle cells from patients with pulmonary hypertension treated with 8-bromo-cyclic guanosine monophosphate (8-Br-cGMP), BAY 41-2272 or BAY 60-2770 compared with control cells.
degradation of the extracellular matrix, the response to wounding and cell adhesion, which are closely related to the pathogenic processes of PH.

Validation of the differentially expressed genes

The potential candidate genes identified using digital gene expression tag profiling were validated using specific primer-based methods. Expression of mRNA levels for genes that were upregulated in the digital gene expression analysis and that may play important roles in regulating extracellular matrix degradation, cell proliferation and angiogenesis were measured using quantitative real-time PCR. Gene expression in human pulmonary artery smooth muscle cells treated with BAY 41-2272 (100 μmol/l for 8 h) is shown in Figure 2. Expression of MMP1, SERPINB2, GREM1 and IL8 was clearly significantly upregulated after BAY 41-2272 treatment compared with control cells.

**GO analysis of differentially expressed genes**

Gene ontology analysis is widely used to describe the molecular functions, cellular components and biological processes of differentially expressed genes in a microarray. As the variation trends of most of the differentially expressed genes were similar in the four treatment groups, GO analysis of the biological process was only performed in the group treated with BAY 41-2272 (100 μmol/l for 8 h). A total of 68 GO items associated with the differentially expressed genes were identified (Table 2). Regulation and negative regulation of cellular process, negative regulation of biological process and regulation of cellular macromolecule biosynthetic process were the most significantly enriched items (low P-value) (Table 2). Moreover, other items associated with the progression of PH such as cell proliferation, cell migration and apoptosis were also enriched.

| Table 1. Significantly up- or downregulated genes in pulmonary artery smooth muscle cells from patients with pulmonary hypertension treated with 8-bromo-cyclic guanosine monophosphate (8-Br-cGMP), BAY 41-2272 or BAY 60-2770 compared with control cells measured using digital gene expression tag profiling. The values given are the number of unique reads, which is an indication of expression levels. |
|---|
| Gene | Controls | 8-Br-cGMP 100 μmol/l for 8 h | BAY 41-2272 100 μmol/l for 8 h | BAY 41-2272 10 μmol/l for 24 h | BAY 60-2770 10 μmol/l for 24 h | Role of gene product |
| MMP1 | 0 | 310 | 508 | 35 | 19 | Extracellular matrix |
| SERPINB2 | 2 | 1401 | 2270 | 163 | 114 | Response to wounding |
| GREM1 | 609 | 10168 | 7528 | 1402 | 1456 | Epithelial to mesenchymal transition |
| IL8 | 36 | 1203 | 1600 | 29 | 25 | Cell adhesion |
| ANGPTL4 | 168 | 3064 | 5275 | 1378 | 516 | Regulation of angiogenesis |
| COL5A3 | 194 | 60 | 12 | 17 | 16 | Collagen protein |
| PDGFRB | 2697 | 865 | 559 | 943 | 1104 | G-protein coupled receptor activity |
| TENC1 | 1591 | 773 | 157 | 1221 | 1209 | Cell proliferation |
| CXCL12 | 3146 | 837 | 298 | 2230 | 2163 | Angiogenesis |
Pathway analysis of differentially expressed genes

To investigate which signal transduction pathways were involved in PH, related pathways were analyzed according to the molecular interaction and reaction networks of the differentially expressed genes in the group treated with BAY 41-2272 (100 μmol/l for 8 h). From this KEGG pathway analysis, a large number of significant pathways were identified (Table 3). A variety of signalling pathways were significantly affected, including pathways in cancer, p53 signalling pathway, nucleotide oligomerization domain (NOD)-like receptor signalling pathway, malaria, mitogen-activated protein kinase (MAPK) signalling pathway, base excision repair and basal cell carcinoma.

Discussion

Despite several advances in therapy, there is currently no curative treatment for PH and its pathophysiology is only partially understood. cGMP, produced by activation of the NO-sGC-cGMP pathway, is a key regulator of vascular smooth muscle cell contractility, growth and differentiation, and has been shown to be associated with PH. However, the regulation of gene expression by cGMP and the physiological effects and functions of cGMP remain to be fully defined.

In the present study, human pulmonary artery smooth muscle cells were treated with 8-Br-cGMP, BAY 41-2272 and BAY 60-2770, activators of the NO-sGC-cGMP pathway, to investigate PH-related differentially expressed genes and signalling pathways. Using digital gene expression tag profiling, a group of downstream genes that are possibly regulated by cGMP were identified. Among the differentially expressed genes detected by Illumina sequencing and confirmed by quantitative real-time PCR, \textit{MMP1}, \textit{SERPINB2}, \textit{GREM1} and \textit{IL8} were identified as candidate marker genes that may be crucial in PH development.
Table 2. Gene ontology items associated with differentially expressed genes in pulmonary artery smooth muscle cells from patients with pulmonary hypertension treated with BAY 41-2272 (100 μmol/l for 8 h) and their corrected P-values.

| Gene ontology item                                      | Corrected P-value |
|--------------------------------------------------------|-------------------|
| Regulation of cellular process                         | 2.27 × 10⁻¹⁰      |
| Negative regulation of biological process              | 6.62 × 10⁻⁹       |
| Negative regulation of cellular process                | 5.91 × 10⁻⁸       |
| Regulation of cellular macromolecule biosynthetic process | 8.27 × 10⁻⁸       |
| Regulation of macromolecule biosynthetic process       | 9.27 × 10⁻⁸       |
| Biological regulation                                  | 4.26 × 10⁻⁷       |
| Developmental process                                  | 4.35 × 10⁻⁷       |
| Multicellular organismal development                   | 9.77 × 10⁻⁷       |
| Cell proliferation                                     | 1.33 × 10⁻⁶       |
| Regulation of biosynthetic process                     | 1.49 × 10⁻⁶       |
| Regulation of primary metabolic process                | 1.53 × 10⁻⁶       |
| Regulation of biological process                       | 2.49 × 10⁻⁶       |
| Regulation of transcription                           | 3.30 × 10⁻⁶       |
| Regulation of transcription, DNA-dependent             | 7.49 × 10⁻⁶       |
| Regulation of cellular biosynthetic process            | 1.07 × 10⁻⁵       |
| Anatomical structure development                       | 1.19 × 10⁻⁵       |
| Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 1.32 × 10⁻⁵ |
| Regulation of RNA metabolic process                    | 1.63 × 10⁻⁵       |
| Regulation of cellular metabolic process               | 1.66 × 10⁻⁵       |
| System development                                     | 2.55 × 10⁻⁵       |
| Regulation of nitrogen compound metabolic process      | 3.04 × 10⁻⁵       |
| Cell migration                                         | 3.87 × 10⁻⁵       |
| Cellular process                                       | 4.28 × 10⁻⁵       |

(continued)
MMP1 encodes matrix metalloprotease-1, a member of the matrix metalloprotease (MMP) family, which are the major proteases involved in tissue remodelling of the extracellular matrix by degrading all types of matrix components. 20 MMPs play an important role in cell proliferation, differentiation, migration, angiogenesis, apoptosis and host defences. Numerous studies have suggested that adjustment of the ratio between MMPs and tissue inhibitors of MMPs could potentiate reverse vascular remodelling in PH. 21 Therefore, understanding the dysregulated expression of MMP1 may provide crucial insights into pulmonary vascular remodelling.

SERPINB2, also known as the plasminogen activator inhibitor-2 gene (PAI-2), encodes a member of a large family of serine protease inhibitors (serpins), which are known to be key regulators of cell proliferation, differentiation, complement activation and apoptosis. 22–25 PAI-1, another member of the serpin family, has been shown to be significantly downregulated in pulmonary artery smooth muscle cells in IPAH and negatively regulates pulmonary artery smooth muscle cell proliferation, suggesting that its downregulation may contribute to pathological vascular remodelling in IPAH. 26 In the present study, PAI-2 (SERPINB2) was shown to be one of the downstream genes affected by the NO-sGC-cGMP pathway; it is possible that PAI-2 may have a similar function to PAI-1 and could alleviate or reverse the vascular remodelling in PH through the regulation of cell proliferation and apoptosis in pulmonary artery smooth muscle cells.

### Table 2. Continued.

| Gene ontology item                              | Corrected P-value |
|-------------------------------------------------|-------------------|
| Regulation of protein metabolic process          | 2.007 × 10⁻²      |
| Regulation of cell proliferation                 | 2.081 × 10⁻²      |
| Regulation of molecular function                 | 2.258 × 10⁻²      |
| Apoptosis                                        | 2.339 × 10⁻²      |
| Negative regulation of DNA binding              | 2.551 × 10⁻²      |
| Response to organic substance                    | 2.620 × 10⁻²      |
| Regulation of phosphate metabolic process        | 3.041 × 10⁻²      |
| Regulation of phosphorus metabolic process       | 3.041 × 10⁻²      |
| Response to stress                               | 3.133 × 10⁻²      |
| Phosphorus metabolic process                     | 3.607 × 10⁻²      |
| Regulation of DNA binding                        | 3.803 × 10⁻²      |
| Positive regulation of macromolecule metabolic process | 4.082 × 10⁻²   |
| Negative regulation of macromolecule metabolic process | 4.321 × 10⁻²   |
| Regulation of anatomical structure size          | 4.540 × 10⁻²      |
| Regulation of phosphorylation                    | 4.572 × 10⁻²      |
| Cellular component organization or biogenesis    | 4.639 × 10⁻²      |
| Positive regulation of biological process         | 4.956 × 10⁻²      |

### Table 3. Identification of significant signal transduction pathways based on an analysis of differentially expressed genes in pulmonary artery smooth muscle cells treated with BAY 41-2272 (100 μmol/l for 8 h).

| Pathway                              | Q-value          |
|--------------------------------------|------------------|
| Pathways in cancer                   | 1.760569 × 10⁻⁵  |
| p53 signalling pathway               | 1.290269 × 10⁻⁴  |
| NOD-like receptor signalling pathway | 2.943706 × 10⁻³  |
| Malaria                              | 8.883089 × 10⁻³  |
| MAPK signalling pathway              | 9.527016 × 10⁻³  |
| Base excision repair                 | 1.002455 × 10⁻²  |
| Basal cell carcinoma                 | 1.336772 × 10⁻²  |

NOD, nucleotide oligomerization domain; MAPK, mitogen-activated protein kinase.
**GREM1** encodes a member of the bone morphogenic protein antagonist family. It may play a role in regulating organogenesis, body patterning and tissue differentiation.\(^{27}\) **IL8** encodes interleukin-8, also known as CXCL8, which is a chemokine produced by macrophages and other cell types that is an important mediator of the immune reaction in the innate immune system response.\(^{28}\) The functions of **GREM1** and **IL8** in PH have not been reported and their roles require further investigation.

In the light of the results of the present study, further investigations into the expression and functions of the protein products of these genes in PH using a greater number of samples are warranted.

To better understand the molecular events involved in the development of PH, functional enrichment analysis of the differentially expressed genes was performed. The results indicated that the enriched biological processes and pathways were very similar following activation of the NO-sGC-cGMP pathway irrespective of the activating agent. Using GO analysis, regulation of cellular process, biological process and cellular macromolecule biosynthetic process were the most significantly enriched items in the present study. Pathway analysis can reveal the distinct biological processes and identify signalling pathways; in the present study, enriched categories included pathways in cancer, p53 signalling pathway, NOD-like receptor signalling pathway, malaria, MAPK signalling pathway, base excision repair and basal cell carcinoma. Interestingly, a number of these pathways (pathways in cancer, p53 signalling pathway and MAPK signalling pathway) are involved in cell proliferation, cell differentiation and cell apoptosis,\(^{29,30}\) which have been reported to be associated with the vascular remodelling seen during PH progression.\(^{31,32}\) These differentially expressed genes may be potent regulators of pulmonary artery smooth muscle cells and dysregulation may lead to the development of pulmonary vascular remodelling.

The differentially expressed genes identified in the present study are probably important contributors to the pathogenesis of PH. However, how cGMP regulates these differentially expressed genes and how these genes regulate vascular remodelling needs to be further investigated. The functions of the other items identified by pathway analysis may also play a role in PH that has not been elucidated yet. Validation and investigation of the downregulated genes will be undertaken in the future.

In conclusion, the present study identified some differentially expressed genes and related pathways regulated by the NO-sGC-cGMP signal pathway, and found that most of the differentially expressed genes were involved in cell proliferation, cell migration and apoptosis, which might contribute to the pathological pulmonary vascular remodelling in PH. These results may provide a novel insight into the molecular mechanisms of PH, especially those involved in pulmonary vascular remodelling. Further studies on these identified genes and signalling pathways may lead to the discovery of new drug targets for PH therapy.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This work was supported by the National High Technology Research and Development Program (grant 2012AA02A511), the National Department Public Benefit Research Foundation (no. 201302008), the National Key Technology Research and Development Program (grant 2013BAI09B00) and the National Natural Science Foundation of China (grant 81400036).
References

1. Gaine S. Pulmonary hypertension. *JAMA* 2000; 284: 3160–3168.
2. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1993; 328: 1732–1739.
3. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. *Chest* 2012; 141: 210–221.
4. Pilz RB and Casteel DE. Regulation of gene expression by cyclic GMP. *Circ Res* 2003; 93: 1034–1046.
5. Stasch JP and Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. *Handb Exp Pharmacol* 2013; 218: 279–313.
6. Schmidt HH, Schmidt PM and Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. *Handb Exp Pharmacol* 2009; 191: 309–339.
7. Stasch JP and Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. *Handb Exp Pharmacol* 2009; 191: 277–308.
8. Martin NI, Derbyshire ER and Marletta MA. Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1. *Bioorg Med Chem Lett* 2007; 17: 4938–4941.
9. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. *Expert Opin Investig Drugs* 2011; 20: 567–576.
10. Zhao Y, Brandish PE, Di Valentin M, et al. Inhibition of soluble guanylate cyclase by ODQ. *Biochemistry* 2000; 39: 10848–10854.
11. Koelsing D, Mullershausen F, Lange A, et al. Negative feedback in NO/cGMP signalling. *Biochem Soc Trans* 2005; 33: 1119–1122.
12. Xiong CM, Lu XL, Shan GL, et al. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. *J Clin Pharmacol* 2012; 52: 425–431.
13. Ramani GV and Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. *Drug Des Devel Ther* 2010; 4: 61–70.
14. Mullershausen F, Russwurm M, Friebe A, et al. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41–2272. *Circulation* 2004; 109: 1711–1713.
15. Kume T, Ito R, Taguchi R, et al. Serofendic acid promotes stellation induced by cAMP and cGMP analogs in cultured cortical astrocytes. *J Pharmacol Sci* 2009; 109: 110–118.
16. Li R, Yu C, Li Y, et al. SOAP2: an improved ultrafast tool for short read alignment. *Bioinformatics* 2009; 25: 1966–1967.
17. Wang Z, Gerstein M and Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009; 10: 57–63.
18. Gu S, Su P, Yan J, et al. Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension. *Int J Mol Med* 2014; 33: 277–300.
19. Kamehisa M and Goto S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000; 28: 27–30.
20. Brumann M, Kusmenkov T, Ney L, et al. Concentration kinetics of serum MMP-9 and TIMP-1 after blunt multiple injuries in the early posttraumatic period. *Mediators Inflamm* 2012; 2012: 435463.
21. Chelladurai P, Seeger W and Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. *Eur Respir J* 2012; 40: 766–782.
22. Bonecza J, Przygodzka P, Papiewska-Pajak I, et al. Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli. *J Biol Chem* 2011; 286: 43164–43171.
23. Hibino T, Matsuda Y, Takahashi T, et al. Suppression of keratinocyte proliferation by plasminogen activator inhibitor-2. *J Invest Dermatol* 1999; 112: 85–90.
24. Kumar S and Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. *J Biol Chem* 1991; 266: 20960–20964.
25. Zhou HM, Bolon I, Nichols A, et al. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes.
enhances papilloma formation in transgenic mice. *Cancer Res* 2001; 61: 970–976.

26. Kouri FM, Queisser MA, Königshoff M, et al. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. *Int J Biochem Cell Biol* 2008; 40: 1872–1882.

27. Wang DJ, Zhi XY, Zhang SC, et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. *Oncol Rep* 2012; 27: 58–64.

28. Allen TC and Kurdowska A. Interleukin 8 and acute lung injury. *Arch Pathol Lab Med* 2014; 138: 266–269.

29. Vacas E, Muñoz-Moreno L, Fernández-Martínez AB, et al. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression. *Int J Biochem Cell Biol* 2014; 53: 295–301.

30. Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. *Cell Death Dis* 2014; 5: e1488.

31. Jacquin S, Rincheval V, Mignotte B, et al. Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats. *PLoS One* 2015; 10: e0131940.

32. Gao J, Chen L, Zeng J, et al. The involvement of aquaporin 1 in the hepatopulmonary syndrome rat serum-induced migration of pulmonary arterial smooth muscle cells via the p38-MAPK pathway. *Mol Biosyst* 2015; 11: 3040–3047.